FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

FibroBiologics (NASDAQ:FBLG) closed a private placement raising approximately $3.0 million in gross proceeds through 4,081,633 common shares (or pre-funded warrants) plus accompanying series A and short-term series B warrants priced at $0.735 per share.

Total potential gross proceeds from full cash exercise of all warrants are about $6.0 million, with funds intended for working capital and general corporate purposes.

Positive

• Approximately $3.0 million in gross proceeds raised via private placement
• Up to approximately $6.0 million in additional proceeds possible from full warrant exercises
• Financing structured with both series A and short-term series B warrants at $0.735 exercise price

Negative

• Issuance of 4,081,633 new shares of common stock and related warrants creates shareholder dilution
• Further dilution possible if up to 8,163,266 series A and B warrants are fully exercised
• No assurance that series A and B warrants will be exercised or provide additional cash proceeds

News Market Reaction – FBLG

+19.22%

12 alerts

+19.22% Session close to close

+6.4% Peak Tracked

-11.0% Trough Tracked

$4.86M Market Cap

1.2x Rel. Volume

In the Jun 30 session, FBLG gained 19.22%, reflecting a significant positive market reaction. Argus tracked a peak move of +6.4% during that session. Argus tracked a trough of -11.0% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +19.2% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +19.2% in the session following this news. A strong positive reaction aligns with prior financing news, where a similar private placement saw about 12.67% upside. Investors may be focusing on the $3.0M upfront cash, though future warrant exercises could increase share count.

Key Figures

Private placement size: $9.0 million Upfront proceeds: $3.0 million Potential warrant proceeds: approximately $6.0 million +5 more

8 metrics

Private placement size $9.0 million Total potential gross proceeds including warrants

Upfront proceeds $3.0 million Gross proceeds from initial closing

Potential warrant proceeds approximately $6.0 million Additional gross proceeds if series A and B warrants fully exercised

Common shares issued 4,081,633 shares Common stock (or pre-funded warrants) sold in private placement

Series A warrants 4,081,633 warrants Series A warrants to purchase common stock

Purchase price $0.735 per share Price of common stock in private placement

Pre-funded warrant price $0.73499 per pre-funded warrant Purchase price in lieu of common stock

Warrant term five years Series A warrants expire five years after approval and effectiveness triggers

Previous Private placement Reports

1 past event · Latest: Jun 26 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 26	Private placement pricing	Neutral	+12.7%	Announced at-the-market private placement raising upfront cash and warrant funding.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Limited tagged history: the prior private placement headline coincided with a double‑digit positive move in the shares.

Key Terms

private placement, pre-funded warrants, resale registration statement, registration rights agreement, +2 more

6 terms

private placement financial

"today announced the closing of its previously announced private placement for the purchase"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrants financial

"shares of common stock (or pre-funded warrants in lieu thereof), series A warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

resale registration statement regulatory

"later of the Stockholder Approval Date and the effective date (the "Effective Date") of the resale registration statement"

A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.

registration rights agreement regulatory

"Pursuant to a registration rights agreement with investors, the Company has agreed"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

section 4(a)(2) regulatory

"offered in a private placement under Section 4(a)(2) of the Securities Act of 1933"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

regulation d regulatory

"and/or Regulation D promulgated thereunder and, along with the shares of common stock"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

 $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants

HOUSTON, June 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 4,081,633 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 4,081,633 shares of common stock and short-term series B warrants to purchase up to 4,081,633 shares of common stock at a purchase price of $0.735 per share of common stock (or $0.73499 per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and the short-term series B warrants have an exercise price of $0.735 per share and are exercisable on or after the effective date of stockholder approval (the "Stockholder Approval Date") of the issuance of the shares of common stock upon exercise of the warrants (the "Stockholder Approval"). The series A warrants expire five years from the later of the Stockholder Approval Date and the effective date (the "Effective Date") of the resale registration statement registering the shares of common stock issuable upon exercise of the series warrants, and the short-term series B warrants expire eighteen months from the later of the Stockholder Approval Date and the Effective Date.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds from the offering were approximately $3.0 million, before deducting placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series A and series B warrants, if fully exercised on a cash basis, will be approximately $6.0 million. No assurance can be given that any of the series warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the series warrants. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities issued in the private placement and shares of common stock underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with investors, the Company has agreed to file a resale registration statement covering the securities described above.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About FibroBiologics, Inc.

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the anticipated use of proceeds from the offering; the potential exercise of the series warrants prior to their expiration and potential proceeds therefrom, and the receipt of Stockholder Approval. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) the unpredictable relationship between R&D and preclinical results and clinical study results; (c) the ability of FibroBiologics to successfully prosecute its patent applications, (d) FibroBiologics' ability to manufacture its product candidates; (e) FibroBiologics' ability to conduct clinical trials; and (f) market and other conditions. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com 

Investor Contact:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com 

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-announces-closing-of-up-to-9-0-million-private-placement-priced-at-the-market-under-nasdaq-rules-302813580.html

SOURCE FibroBiologics, Inc.

FAQ

What did FibroBiologics (NASDAQ:FBLG) announce about its June 29, 2026 private placement?

FibroBiologics announced closing a private placement raising about $3.0 million in gross proceeds. According to FibroBiologics, the deal includes 4,081,633 common shares (or pre-funded warrants) plus series A and short-term series B warrants, all priced at-the-market under Nasdaq rules.

How many FibroBiologics (FBLG) shares and warrants were issued in the June 2026 financing?

FibroBiologics issued 4,081,633 common shares (or pre-funded warrants) and matching series A and series B warrants. According to FibroBiologics, each warrant series covers up to 4,081,633 shares of common stock, creating potential for additional equity if investors exercise the warrants.

What is the share and warrant exercise price in FibroBiologics (FBLG) June 2026 private placement?

The purchase and warrant exercise price is $0.735 per share. According to FibroBiologics, common stock and accompanying warrants were sold at $0.735 per share, while pre-funded warrants were priced at $0.73499 with series A and B warrants also exercisable at $0.735 per share.

How will FibroBiologics (NASDAQ:FBLG) use the proceeds from the June 2026 private placement?

FibroBiologics plans to use net proceeds for working capital and general corporate purposes. According to FibroBiologics, the offering generated about $3.0 million in gross proceeds, before fees and expenses, with up to approximately $6.0 million more possible from full warrant exercises.

What are the terms and expirations of FibroBiologics series A and B warrants from 2026?

Series A and B warrants each have a $0.735 exercise price and activate after stockholder approval. According to FibroBiologics, series A warrants expire five years after approval and registration effectiveness, while short-term series B warrants expire eighteen months after those same dates.

What is the total potential size of FibroBiologics (FBLG) June 2026 private placement including warrants?

Total potential gross proceeds are up to approximately $9.0 million. According to FibroBiologics, the company received about $3.0 million upfront, with around $6.0 million in additional gross proceeds possible if all series A and series B warrants are exercised on a cash basis.

Is the FibroBiologics June 2026 private placement registered under the Securities Act?

The securities were issued in an unregistered private placement under Section 4(a)(2) and Regulation D. According to FibroBiologics, resale requires an effective registration statement or exemption, and the company agreed to file a resale registration statement for the offered securities.